Eyenovia (Eyenovia) Days Sales Outstanding : 0.00 (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Eyenovia Days Sales Outstanding?

Eyenovia's average Accounts Receivable for the three months ended in Mar. 2024 was $0.00 Mil. Eyenovia's Revenue for the three months ended in Mar. 2024 was $0.01 Mil. Hence, Eyenovia's Days Sales Outstanding for the three months ended in Mar. 2024 was 0.00.

The historical rank and industry rank for Eyenovia's Days Sales Outstanding or its related term are showing as below:

EYEN's Days Sales Outstanding is not ranked ^*
in the Biotechnology industry.
Industry Median: 72.545
* Ranked among companies with meaningful Days Sales Outstanding only.

Eyenovia's Days Sales Outstanding stayed the same from Mar. 2023 (0.00) to Mar. 2024 (0.00).

Eyenovia Days Sales Outstanding Historical Data

The historical data trend for Eyenovia's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eyenovia Days Sales Outstanding Chart

Eyenovia Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

Eyenovia Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Days Sales Outstanding	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Eyenovia's Days Sales Outstanding

For the Biotechnology subindustry, Eyenovia's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eyenovia's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eyenovia's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Eyenovia's Days Sales Outstanding falls into.

Eyenovia Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Eyenovia's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0.004	*	365
=	0					/	0.004	*	365
=	0.00

Eyenovia's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding (Q: Mar. 2024 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2023 )	+	Accounts Receivable (A: Mar. 2024 ))	/	count )	/	Revenue (A: Mar. 2024 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0.005	*	365 / 4
=	0					/	0.005	*	365 / 4
=	0.00

Eyenovia (NAS:EYEN) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Eyenovia Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Eyenovia's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Eyenovia (Eyenovia) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eyenovia Inc (NAS:EYEN) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

295 Madison Avenue, Suite 2400, New York, NY, USA, 10017

Website

https://www.eyenovia.com

Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.

Executives

Michael M Rowe	director, officer: Chief Executive Officer	C/O EYENOVIA, INC., 501 FIFTH AVENUE, SUITE 1404, NEW YORK NY 10017
Ellen R Strahlman	director	ALTRIA GROUP, INC., 6601 W. BROAD STREET, RICHMOND VA 23230
Stuart M. Grant	10 percent owner	11 SUMMIT LANE, GREENVILLE DE 19807
Ram Palanki	director	C/O EYENOVIA, INC, 295 MADISON AVENUE SUITE 2400, NEW YORK NY 10017
Rachel Jacobson	director	C/O EYENOVIA INC, 295 MADISON AVENUE SUITE 2400, NEW YORK NY 10017
John P Gandolfo	officer: Chief Financial Officer	62 TERRACE ROAD, WAYNE NJ 07470
Bren Kern	officer: Chief Operating Officer	295 MADISON AVENUE, SUITE 2400, C/O EYENOVIA, INC., NEW YORK NY 10017
Mather Charles E Iv	director	C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Tsontcho Ianchulev	director	501 FIFTH AVENUE, SUITE 1404, NEW YORK NY 10017
Stephen Keith Benjamin	director	135 NORTH CHURCH STREET, SPARTANBURG SC 29306
Julia A Haller	director	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Lee Kenneth B Jr	director	7100 WEST CREDIT AVENUE, SUITE 101, C/O ARALEZ PHARMACEUTICALS INC., MISSISSAUGA A6 L5N 0E4
Curt H Labelle	director	C/O INVESTOR GROWTH CAPITAL, INC., 630 FIFTH AVENUE, SUITE 1965, NEW YORK NY 10011
Anthony Y Sun	director	C/O AISLING CAPITAL, 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10106
Fredric N Eshelman	director	PPD INC, 929 NORTH FRONT STREET, WILMINGTON NC 28401